Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation

O’Donnell, Margaret

doi:10.1002/9780470987070.ch60

Cited by 3 publications

(4 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17,19,22 AIHA caused by this mechanism can be seen in all types of allo-HSCT including CBT and haplo-HSCT, and even in ABO-matched transplantations. 23 The above mechanisms show that suppression of the plasma cells that are producing antibodies is the requirement for a successful transplantation. Post-transplantation AIHA poses an extraordinary challenge to transplant surgeons.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Refractory autoimmune haemolytic anaemia following allogenic haematopoietic stem cell transplantation: successful treatment of rituximab

Huang

Zhu

et al. 2019

J Int Med Res

View full text Add to dashboard Cite

Objective To investigate the effectiveness and safety of rituximab in treating autoimmune haemolytic anaemia (AIHA) after allogeneic haematopoietic stem cell transplantation (allo-HSCT). Methods Patients with refractory AIHA following allo-HSCT were treated once-weekly with rituximab 375 mg/m2 for a total of four doses. In an animal study, recipient CB6F1 mice were conditioned with busulfan/fludarabine and transplanted with splenocytes and T-cell-depleted bone marrow from C57Bl/6 mice. In this animal model, anti-CD20 monoclonal antibody (mAb) was evaluated to see if it could prevent graft versus host disease (GVHD). GVHD was monitored by body weight loss, GVHD clinical scores and the survival of each group of mice. Histopathological analyses of the skin, intestine, liver and lung were used to analyse the severity of GVHD. Results After rituximab therapy, refractory AIHA was resolved in all four patients as shown by increased haemoglobin levels. B-cell proportions were reduced with a relative increase of the proportions of T-cells following rituximab treatment. None of the four patients experienced chronic GVHD. In the animal model, anti-CD20 mAb treatment reduced GVHD. Conclusions Rituximab therapy deserves consideration for the treatment of post-HSCT patients with refractory AIHA. Further studies are needed to define the therapeutic role of this anti-CD20 mAb.

show abstract

Section: Discussionmentioning

confidence: 99%

“…26 Usually, AIHA occurs concomitantly with Epstein-Barr virus (EBV) and/or monoclonal gammopathy. 23 Rituximab can also be used for treating EBV and monoclonal gammopathy after transplantation. 27 Treating patients with rituximab can result in AIHA and monoclonal gammopathy resolving as well as EBV-DNA becoming undetectable.…”

Section: Discussionmentioning

confidence: 99%

Refractory autoimmune haemolytic anaemia following allogenic haematopoietic stem cell transplantation: successful treatment of rituximab

Huang

Zhu

et al. 2019

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…216 The infusion of incompatible red blood cells or immunocompetent B lymphocytes may provoke acute or delayed hemolytic transfusion reactions; therefore, red cell and/or plasma depletion may be required, and careful transfusion practices are critical. 216 The infusion of incompatible red blood cells or immunocompetent B lymphocytes may provoke acute or delayed hemolytic transfusion reactions; therefore, red cell and/or plasma depletion may be required, and careful transfusion practices are critical.…”

Section: Management Of Red Blood Cell Incompatibilitymentioning

confidence: 99%

Collection and Processing of Peripheral Blood Stem Cells and Bone Marrow

Rowley¹,

Benn²

2007

Blood Banking and Transfusion Medicine

View full text Add to dashboard Cite

“…In 30 to 40 percent of transplants, recipient and donor harbor different ABO antigens on their RBCs. 5 Even more commonly, recipients and donors have different non-ABO RBC antigens. In this setting, ensuring an adequate and compatible blood supply requires careful attention.…”

mentioning

confidence: 99%

Review: immunohematologic aspects of allogeneic hematopoietic progenitor cell transplantation

Laroche¹,

Eastlund²,

McCullough

2004

Immunohematology

View full text Add to dashboard Cite

Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation

Cited by 3 publications

References 87 publications

Refractory autoimmune haemolytic anaemia following allogenic haematopoietic stem cell transplantation: successful treatment of rituximab

Refractory autoimmune haemolytic anaemia following allogenic haematopoietic stem cell transplantation: successful treatment of rituximab

Collection and Processing of Peripheral Blood Stem Cells and Bone Marrow

Review: immunohematologic aspects of allogeneic hematopoietic progenitor cell transplantation

Contact Info

Product

Resources

About